Free
Clinical Science  |   March 1996
Preservation of the Ratio of Cerebral Blood Flow/Metabolic Rate for Oxygen during Prolonged Anesthesia with Isoflurane, Sevoflurane, and Halothane in Humans
Author Notes
  • (Kuroda, Murakami, Tsuruta) Staff Anesthesiologist, Department of Anesthesia, Yamaguchi Rosai Hospital, Yamaguchi, Japan.
  • (Murakawa) Chief Anesthesiologist, Department of Anesthesia, Yamaguchi Rosai Hospital, Yamaguchi, Japan.
  • (Sakabe) Professor and Chairman, Department of Anesthesiology-Resuscitology, Yamaguchi University Hospital, Yamaguchi, Japan.
  • Received from the Yamaguchi Rosai Hospital, Yamaguchi, Japan. Submitted for publication May 1, 1995. Accepted for publication November 16, 1995. Presented at the XVII International Symposium on cerebral blood flow and metabolism, Cologne, Germany, July 2–6, 1995.
  • Address reprint requests to Dr. Kuroda: Department of Anesthesia, Himeji National Hospital, 68 Honmachi, Himeji, Hyogo 670, Japan.
Article Information
Clinical Science
Clinical Science   |   March 1996
Preservation of the Ratio of Cerebral Blood Flow/Metabolic Rate for Oxygen during Prolonged Anesthesia with Isoflurane, Sevoflurane, and Halothane in Humans
Anesthesiology 3 1996, Vol.84, 555-561. doi:
Anesthesiology 3 1996, Vol.84, 555-561. doi:
IT has been reported in several animal studies, [1–6] with some exceptions, [7,8] that the increase in cerebral blood flow (CBF) produced by isoflurane and halothane resolves over time despite the maintenance of stable depth of anesthesia. The mechanism for this gradual return of CBF to preanesthetic level is unclear, but it does not appear to be ascribed to a change in cerebral metabolic rate for oxygen (CMRO2). [1–6] .
Unlike animal experiments, no human study has found support for the CBF declines over time. In the patients anesthetized with desflurane or isoflurane, there was no decrease in CBF over time. [9,10] Because of technical difficulties, repeated measurements of CBF with a short time interval were not performed in humans for a prolonged period during surgical anesthesia. Using transcranial Doppler, Bisonnette et al. demonstrated that pulsatility and blood flow velocity remained stable during 2 h isoflurane anesthesia in children. [11] The discrepancies among the previous reports, including animal experiments and human studies, prompted us to determine CBF equivalent (CBF divided by CMRO2), which can be repeatedly measured under constant end-tidal concentration of volatile anesthetics during prolonged surgery. We therefore designed this study to (1) examine the effect of time course on CBF equivalent every 20 min and (2) compare the effect of isoflurane, sevoflurane, and halothane on CBF equivalent.
Materials and Methods
The study protocol was approved by the Ethical Committee for Human Study of the Yamaguchi Rosai Hospital, and informed consent was obtained from each patient. Twenty-four ASA physical status 1 or 2 patients (10 males, 14 females) were randomly assigned to three groups receiving isoflurane, sevoflurane, or halothane during elective surgery. Ages of the patients ranged from 22 to 80 yr. Preoperative examinations revealed neither cardiopulmonary nor neurologic disorders in all patients. Surgical procedures included major orthopedic and abdominal surgery. Atropine sulfate (0.5 mg) was given intramuscularly 30 min before induction. Anesthesia was induced with the selected volatile anesthetic in an air-oxygen mixture adjusted to obtain FIO2of 0.35, and inspired concentration of volatile anesthetic was increased to 3–4% over 3–4 min. Tracheal intubation was facilitated with intravenous administration of 8 mg vecuronium bromide. After intubation, end-tidal concentration of the selected volatile anesthetic was adjusted to an age-appropriate level [12–15] of 0.5 MAC, then increased to 1.0 MAC before surgery and maintained at 1.5 MAC for the surgical procedure. Actual end-tidal concentrations (22–39, 40–59, 60–80 yr) for 1.0 MAC were as follows: 1.27, 1.15, 1.04 (isoflurane); 0.82, 0.75, 0.67 (halothane); and 1.96, 1.71, 1.48 (sevoflurane), respectively. Patients' lungs were mechanically ventilated to maintain normocapnia, and FIO2was kept at 0.35. The end-tidal concentrations of carbon dioxide and volatile anesthetic were continuously monitored with a calibrated infrared gas analyzer (Capnomac Ultima, Datex, Helsinki, Finland). Apart from vecuronium, no other drugs were administered during the surgical procedure except phenylephrine, to maintain cerebral perfusion pressure (CPP; see below). The nasopharyngeal temperature was monitored by a calibrated thermistor probe and kept at 36.0–37.0 degrees C using a cooling-warming water mattress. Bilateral unipolar (ear-lap as a reference electrode), frontal, and occipitotemporal electroencephalograms (EEG) were monitored and recorded continuously (Neuropack 8, Nihon Kohden, Tokyo, Japan). The electrocardiogram also was monitored. A 22-G Teflon indwelling catheter was placed in the radial artery, and an 18-G Medicut catheter was placed in the right jugular bulb for blood sampling and pressure measurement. The position of the jugular bulb catheter tip was confirmed by x-ray. The arterial and internal jugular venous pressures were measured by strain gauge transducers with the zero point at the mastoid process and were recorded on a polygraph (Lifescope 14, Nihon Kohden, Tokyo). The difference between mean arterial blood pressure and mean jugular venous pressure was defined as CPP. CPP was maintained greater than 60 mmHg with a continuous infusion of phenylephrine (0.2–0.9 micro gram *symbol* kg sup -1 *symbol* min sup -1), if necessary. Arterial and internal jugular venous blood samples were obtained every 20 min and analyzed for oxygen tension (PO2), carbon dioxide tension (PCO2), bicarbonate ion concentration, and pH with a blood gas analyzer (ABL505, Radiometer, Copenhagen, Denmark) at 37.0 degrees C. Hemoglobin oxygen saturations and hemoglobin concentrations were measured spectrophotometrically (OSM3, Radiometer). Oxygen content was calculated from the hemoglobin oxygen-carrying capacity and the amount of dissolved oxygen (estimated from PO2and oxygen solubility). CBF equivalent was calculated as the reciprocal of arterial-jugular venous oxygen content difference.
Data Analysis
Data are expressed as mean+/-SD. Between-group comparisons of demographic data and intraoperative fluid balances were made by one-way analysis of variance (ANOVA). Gender distribution between groups was compared by chi-square analysis. Physiologic variables were compared by the two-way ANOVA for repeated measures. For the statistical analysis on CBF equivalent and internal jugular venous PO2(Pjvo2), the data were separated into two parts, the initial dose-response data (0.5, 1.0, 1.5 MAC) and the time course data at 1.5 MAC. Two-way ANOVA for repeated measures was applied on each part. Bonferroni's post hoc test was applied for between-group comparisons as indicated. Statistical significance was assumed when P < 0.05.
Results
A summary of demographic data is shown in Table 1. There were no significant differences among three groups of demographic data and intraoperative fluid balances. Heart rate ranged from 54 to 120 beats/min with different agents. Hemoglobin concentration was stable (8.6–14.9 g/dl), as was PaO2(66–210 mmHg) and nasopharyngeal temperature (35.9–37.4 degrees C). There were no significant differences among groups in these variables.
Table 1. Demographic and Intraoperative Data
Image not available
Table 1. Demographic and Intraoperative Data
×
(Table 2) lists CPP, PaCO2, and phenylephrine doses at selected times during the study. CPP in the sevoflurane group was significantly (P < 0.05) greater than those in the halothane and isoflurane groups. Nevertheless, CPP in all groups was maintained within physiologic range. The total number of patients given phenylephrine was five, six, and five in the isoflurane, halothane, and sevoflurane groups, respectively. PaCO2was unchanged for 4 h, and there were no significant differences among three groups.
Table 2. Physiologic Variables
Image not available
Table 2. Physiologic Variables
×
(Figure 1) shows the time course of the changes of CBF equivalent and Pjvo2. CBF equivalents at 0.5 MAC of isoflurane, halothane, and sevoflurane were 21+/-4, 20+/-3, and 21 +/-5 ml blood/ml oxygen, respectively. CBF equivalent and Pjvo2significantly (P < 0.01) increased in a dose-dependent manner at volatile anesthetic concentrations of 0.5, 1.0, and 1.5 MAC. At 1.5 MAC, the increase of CBF equivalent and Pjvo2with all anesthetics was maintained increased with minimal fluctuation for 3 h. The average value of the CBF equivalent during 3 h at 1.5 MAC was significantly (P < 0.01) greater in the isoflurane group (45+/-8 ml blood/ml oxygen) than in the halothane (32+/-8) and sevoflurane (31+/-8) groups. The average value of Pjvo2in the isoflurane group (55 +/-5 mmHg) was significantly (P < 0.01) greater than that in the sevoflurane group (48+/-6), but it was not significantly different from that of the halothane group (50+/-4).
Figure 1. Time course of the changes of cerebral blood flow (CBF) equivalent and internal jugular venous oxygen tension (Pjvo2). Values are expressed as mean+/-SD. CBF equivalents at 0.5 MAC of isoflurane, halothane, and sevoflurane were 21+/-4, 20+/- 3, and 21+/-5 ml blood/ml oxygen, respectively. CBF equivalent and Pjvo2significantly (P < 0.01) increased in a dose-dependent manner volatile anesthetic concentrations (0.5, 1.0, 1.5 MAC). Once anesthetic concentration reached 1.5 MAC, the increase in CBF equivalent and Pjvo2in all groups were maintained increased with minimal fluctuation. When compared at 1.5 MAC, the average value of CBF equivalent in the isoflurane group (45+/-8 ml blood/ml oxygen) is significantly (P < 0.01) greater than that in the halothane (32+/- 8) and sevoflurane (31+/-8) groups. When compared at 1.5 MAC, the average value of Pjvo2in the isoflurane group (55+/-5 mmHg) is significantly (P < 0.01) greater than that in the sevoflurane group (48 +/-6), but it was not significantly different from that in the halothane group (50+/-4).
Figure 1. Time course of the changes of cerebral blood flow (CBF) equivalent and internal jugular venous oxygen tension (Pjvo2). Values are expressed as mean+/-SD. CBF equivalents at 0.5 MAC of isoflurane, halothane, and sevoflurane were 21+/-4, 20+/- 3, and 21+/-5 ml blood/ml oxygen, respectively. CBF equivalent and Pjvo2significantly (P < 0.01) increased in a dose-dependent manner volatile anesthetic concentrations (0.5, 1.0, 1.5 MAC). Once anesthetic concentration reached 1.5 MAC, the increase in CBF equivalent and Pjvo2in all groups were maintained increased with minimal fluctuation. When compared at 1.5 MAC, the average value of CBF equivalent in the isoflurane group (45+/-8 ml blood/ml oxygen) is significantly (P < 0.01) greater than that in the halothane (32+/- 8) and sevoflurane (31+/-8) groups. When compared at 1.5 MAC, the average value of Pjvo2in the isoflurane group (55+/-5 mmHg) is significantly (P < 0.01) greater than that in the sevoflurane group (48 +/-6), but it was not significantly different from that in the halothane group (50+/-4).
Figure 1. Time course of the changes of cerebral blood flow (CBF) equivalent and internal jugular venous oxygen tension (Pjvo2). Values are expressed as mean+/-SD. CBF equivalents at 0.5 MAC of isoflurane, halothane, and sevoflurane were 21+/-4, 20+/- 3, and 21+/-5 ml blood/ml oxygen, respectively. CBF equivalent and Pjvo2significantly (P < 0.01) increased in a dose-dependent manner volatile anesthetic concentrations (0.5, 1.0, 1.5 MAC). Once anesthetic concentration reached 1.5 MAC, the increase in CBF equivalent and Pjvo2in all groups were maintained increased with minimal fluctuation. When compared at 1.5 MAC, the average value of CBF equivalent in the isoflurane group (45+/-8 ml blood/ml oxygen) is significantly (P < 0.01) greater than that in the halothane (32+/- 8) and sevoflurane (31+/-8) groups. When compared at 1.5 MAC, the average value of Pjvo2in the isoflurane group (55+/-5 mmHg) is significantly (P < 0.01) greater than that in the sevoflurane group (48 +/-6), but it was not significantly different from that in the halothane group (50+/-4).
×
Representative EEG patterns at 1 and 4 h are shown in Figure 2. At 1.5 MAC, EEG recordings showed frequent burst (sharp or spike wave, 50–100 micro V) and suppression in the isoflurane group, whereas in the halothane and sevoflurane groups, 13–15-Hz (50–100 micro V) and 9–13-Hz activities (70–100 micro V) were predominant, respectively. These EEG patterns at 1.5 MAC, examined without knowing the sequence of each recording, proved to be relatively unchanged with time during observation period.
Figure 2. Representative electroencephalograms at 1 and 4 h of anesthesia at 1.5 MAC. Electroencephalogram (EEG) recordings showed frequent burst (sharp or spike wave, 50–100 micro V) and suppression in the isoflurane group, whereas in the halothane and sevoflurane groups, 13–15-Hz (50–100 micro V) and 9–13-Hz activities (70–100 micro V) were predominant, respectively. There were no apparent changes in EEG pattern with time in all three groups.
Figure 2. Representative electroencephalograms at 1 and 4 h of anesthesia at 1.5 MAC. Electroencephalogram (EEG) recordings showed frequent burst (sharp or spike wave, 50–100 micro V) and suppression in the isoflurane group, whereas in the halothane and sevoflurane groups, 13–15-Hz (50–100 micro V) and 9–13-Hz activities (70–100 micro V) were predominant, respectively. There were no apparent changes in EEG pattern with time in all three groups.
Figure 2. Representative electroencephalograms at 1 and 4 h of anesthesia at 1.5 MAC. Electroencephalogram (EEG) recordings showed frequent burst (sharp or spike wave, 50–100 micro V) and suppression in the isoflurane group, whereas in the halothane and sevoflurane groups, 13–15-Hz (50–100 micro V) and 9–13-Hz activities (70–100 micro V) were predominant, respectively. There were no apparent changes in EEG pattern with time in all three groups.
×
Discussion
This study demonstrated in humans that CBF equivalent* increased in a dose-dependent manner with all three volatile anesthetics examined. The elevated global CBF relative to oxygen demand was maintained during prolonged (4 h) anesthesia. The results also showed that the CBF equivalent at 1.5 MAC in the isoflurane group was significantly greater than in the halothane and sevoflurane groups.
In general, all volatile anesthetics are considered potent cerebral vasodilators and to increase CBF. It is, however, controversial whether the increase of CBF by volatile anesthetics is maintained for a prolonged period of anesthesia. Many animal studies using dogs and goats revealed that isoflurane- and halothane-induced cerebral hyperemia spontaneously decreased over time. [1–6,16] No definitive explanation has been obtained for this gradual decline of CBF. The decrease of CBF over time may be partially explained in one report [16] by the decrease of CMRO2, probably related to the gradual increase in the depth of anesthesia (although the concentration of anesthetic was not measured). However, in most of the studies, CMRO2was either unchanged [1–5] or increased slightly [6] during the measurement period. Immobilization and/or mechanical ventilation has been postulated as the cause, [1] but this is not conclusive. The time-dependent changes in the status of autoregulation [6] or in the pH of cerebrospinal fluid, [4] and the involvement of alpha/beta-receptor [6] failed to reveal the mechanism.
Some reports have failed to observe the gradual decrease in CBF over time. Roald et al. reported that CBF and CMRO2remained unchanged during isoflurane anesthesia of 3–4 h in dogs using sagittal sinus outflow technique. [7] The authors speculated that the gradual decrease in CBF with time in the previous study [2] might have been caused by the changes in the blood rheology due to exposure to air combined with mechanical destruction by a roller pump. McPherson et al. reported that the CBF measured by the technique of radiolabeled microspheres was increased without decay by isoflurane for 4 h in primates, whereas CMRO2was unchanged over time. [8] Although not conclusive, the different results reported in animals may be due to the differences of species and/or the technique of CBF measurement. In McPherson et al.'s study, at the end of 4 h of isoflurane anesthesia, increased CBF was attenuated by the nitric oxide synthase inhibitor, L-NAME. [8] The authors concluded that sustained production of nitric oxide during prolonged isoflurane anesthesia in monkeys prevents the gradual decrease in CBF. Other recent studies suggested that volatile anesthetic-induced cerebral hyperemia is partially attributed to an increased production of nitric oxide in the rat, pig, and dog. [17–19] Thus, further studies are necessary to determine the contribution of nitric oxide to CBF during prolonged exposure to volatile anesthetics in different species.
Human studies of this subject are limited because repeated measurement of CBF for prolonged periods is not easy in the operating theater. Madsen et al. [9] reported no significant differences of CBF and CMRO2between 1 and 2 h after induction of isoflurane anesthesia in patients with small cerebral tumors. In patients with intracranial mass lesions, Ornstein [10] found no demonstrable decrease in CBF between two times of measurements (3 and 6 h after induction) in desflurane or isoflurane anesthesia (1.25 MAC) using intravenous133Xenon methods during hypocapnia (PaCO225 mmHg). These results suggest that CBF does not change over time during anesthesia in humans. However, the measurements were made only twice. A recent transcranial Doppler study in children showed that pulsatility and blood flow velocity in the middle cerebral artery measured every 15 min remained stable with 90–150 min of isoflurane exposure, [11] suggesting no decay in CBF over time indirectly. The constant CBF equivalent was observed in the current study for prolonged periods of anesthesia at 1.5 MAC. Although CBF and CMRO2were not measured in this study, EEG pattern was relatively unchanged during the 3 h of anesthesia at 1.5 MAC, and it is unlikely that CMRO2had changed markedly over time. Hence, our results suggest that the increase of CBF is maintained during prolonged volatile (isoflurane, halothane, and sevoflurane) anesthesia in humans.
Because our measurements of CBF equivalent were taken while surgery has been ongoing, one may have to consider the possibility of contribution of nociceptive stimulation to the results. It is possible that the decrease of CBF over time observed in many animal studies was due to the gradual decrease of nociceptive stimulation after surgical preparation. However, in goats whose surgical preparations have been completed 10 days before the experiment, the increase in CBF caused by 1% halothane returned to the preanesthetic level over 150 min of anesthesia. [6] In primates, CBF was increased gradually during 4 h of isoflurane anesthesia, the measurements having been started 15 min after the completion of surgical preparation. [8] Furthermore, in the above-mentioned clinical studies, [9–11] CBF (and blood flow velocity) was unchanged during 1.5–6 h of anesthesia, while surgical nociceptive stimulation was of minor importance. From these results, it is unlikely that the lack of CBF decay over time in clinical studies, including the current one, is due to the nociceptive stimulation.
The current results also showed that, at 1.5 MAC, isoflurane possesses greater capability to maintain global CBF relative to CMRO2than does halothane or sevoflurane. CPP in the sevoflurane group was higher than in the isoflurane or halothane groups at 1.5 MAC. However, CPP in all groups was maintained within physiologic range, and there were no significant changes over time. Provided that autoregulation is attenuated at 1.5 MAC, the values of CBF equivalent in the sevoflurane group might have been a bit exaggerated, and hence, the difference of CBF equivalent between isoflurane and sevoflurane groups might have been underestimated. Therefore, the conclusion is not affected.
Because we did not directly measure CBF or CMRO2, we are unable to conclude whether our results that isoflurane possesses greater capability to maintain global CBF relative to CMRO2than halothane or sevoflurane are due to greater vasodilating capability and/or greater metabolic depressive effects. In isoflurane anesthesia, many studies reported that the increase in CBF, if present at all, is smaller, whereas the decrease in CMRO2is greater than the changes observed with halothane. [20] This partly coincides with the experimental results reported by Hansen et al., [21] that isoflurane possesses greater cerebral vasodilating capability relative to CMRO2than halothane. Although Smith reported that CBF equivalent was a function of anesthetic depth (MAC) regardless of volatile anesthetics, [22] we postulate that CBF equivalent depends on MAC as well as on volatile anesthetics used.
In summary, the current study demonstrates that global CBF relative to oxygen demand is markedly increased and maintained during prolonged inhalation of volatile anesthetics in humans. It is impossible to determine whether these data indicate a stable CBF or whether CBF and CMRO2are changing in parallel during the observation period. The unchanging EEG pattern suggests that the former possibility is more likely and that the increase in CBF produced by volatile anesthetics is maintained over time without decay, which has been reported in several animal studies. The current results also suggest that isoflurane possesses greater capability to maintain global CBF relative to CMRO2than does halothane or sevoflurane.
*The CBF equivalent in normal, awake humans is 15+/-3 ml blood/ml oxygen (mean+/-SD) in our department (Sari A, Maekawa T, Tohjo M, Okuda Y, Takeshita H: Effects of althesin on cerebral blood flow and oxygen consumption in man. Br J Anaesth 1976; 48:545–50).
REFERENCES
Raichle ME, Posner JB, Plum F: Cerebral blood flow during and after hyperventilation. Arch Neurol 1970; 23:394-403.
Takeshita H, Michenfelder JD, Theye RA: The effects of morphine and N-allylnormorphine on canine cerebral metabolism and circulation. ANESTHESIOLOGY 1972; 37:605-12.
Boarini DJ, Kassell NF, Coester HC, Butler M, Sokoll MD: Comparison of systemic and cerebrovascular effects of isoflurane and halothane. Neurosurgery 1984; 15:400-9.
Warner DS, Boarini DJ, Kassel NF: Cerebrovascular adaptation to prolonged halothane anesthesia is not related to cerebrospinal fluid pH. ANESTHESIOLOGY 1985; 63:243-8.
Brian JE, Traystman RJ, McPherson RW: Changes in cerebral blood flow over time during isoflurane anesthesia in dogs. J Neurosurg Anesth 1990; 2:122-30.
Albrecht RF, Miletich DJ, Madala LR: Normalization of cerebral blood flow during prolonged halothane anesthesia. ANESTHESIOLOGY 1983; 58:26-31.
Roald OK, Forsman M, Steen PA: The effects of prolonged isoflurane anesthesia on cerebral blood flow and metabolism in the dog. Acta Anaesthesiol Scand 1989; 33:210-3.
McPherson RW, Kirsch JR, Tobin JR, Ghaly RF, Traystman RJ: Cerebral blood flow in primates is increased by isoflurane over time and is decreased by nitric oxide synthase inhibition. ANESTHESIOLOGY 1994; 80:1320-7.
Madsen JB, Cold GE, Hansen ES, Bardrum B: The effect of isoflurane on cerebral blood flow and metabolism in human during craniotomy for small supratentorial cerebral tumors. ANESTHESIOLOGY 1987; 66:332-6.
Ornstein E, Young WL, Fleischer LH, Ostapkovich N: Desflurane and isoflurane have similar effects on cerebral blood flow in patients with intracranial mass lesions. ANESTHESIOLOGY 1993; 79:498-502.
Bisonnette B, Leon JE: Cerebrovascular stability during isoflurane anesthesia in children. Can J Anaesth 1992; 39:128-34.
Gregory GA, Eger EI II, Munson ES: The relationship between age and halothane requirement in man. ANESTHESIOLOGY 1969; 30:488-91.
Stevens WC, Dolan WM, Gibbons RT, White A, Eger EI, Millar RD, de Jong RH, Elashoff RM: Minimum alveolar concentrations (MAC) of isoflurane with and without nitrous oxide in patients of various ages. ANESTHESIOLOGY 1975; 42:197-200.
Katoh T, Ikeda K: The minimum alveolar concentration (MAC) of sevoflurane in humans. ANESTHESIOLOGY 1987; 66:301-3.
Nagayama T, Meguro K, Inada Y: Sevoflurane MAC in the elderly. Masui 1994; 43:238-41.
Turner DM, Kassel NF, Sasaki T, Comair YG, Boarini DJ, Beck DO: Time-dependent changes in cerebral and cardiovascular parameters in isoflurane-nitrous oxide-anesthetized dogs. Neurosurgery 1984; 14:135-41.
McPherson RW, Kirsch JR, Moore LE, Traystman RJ: Nw-nitro-L-arginine methyl ester prevents cerebral hyperemia by inhaled anesthetics in dogs. Anesth Analg 1993; 77:891-7.
Moore LE, Kirsch JR, Helfaer MA, Tobin JR, McPherson RW, Traystman RJ: Nitric oxide and prostanoids contribute to isoflurane-induced cerebral hyperemia in pigs. ANESTHESIOLOGY 1994; 80:1328-37.
Wei HM, Weiss HR, Sinha AK, Chi OZ: Effects of nitric oxide synthase inhibition on regional cerebral blood flow and vascular resistance in conscious and isoflurane-anesthetized rats. Anesth Analg 1993; 77:880-5.
Sakabe T, Nakakimura K: Effects of anesthetic agents and other drugs on cerebral blood flow, metabolism, and intracranial pressure, Anesthesia and Neurosurgery. Edited by Cottrel JE, Smith DS. St. Louis, Mosby, 1994, pp 149-74.
Hansen TD, Warner DS, Todd MM, Vust LJ: The role of cerebral metabolism in determining the local cerebral blood flow effects of volatile anesthetics: Evidence for persistent flow-metabolism coupling. J Cereb Blood Flow Metab 1989; 9:323-8.
Smith AL: Dependence of cerebral venous oxygen tension on anesthetic depth. ANESTHESIOLOGY 1973; 39:291-8.
Figure 1. Time course of the changes of cerebral blood flow (CBF) equivalent and internal jugular venous oxygen tension (Pjvo2). Values are expressed as mean+/-SD. CBF equivalents at 0.5 MAC of isoflurane, halothane, and sevoflurane were 21+/-4, 20+/- 3, and 21+/-5 ml blood/ml oxygen, respectively. CBF equivalent and Pjvo2significantly (P < 0.01) increased in a dose-dependent manner volatile anesthetic concentrations (0.5, 1.0, 1.5 MAC). Once anesthetic concentration reached 1.5 MAC, the increase in CBF equivalent and Pjvo2in all groups were maintained increased with minimal fluctuation. When compared at 1.5 MAC, the average value of CBF equivalent in the isoflurane group (45+/-8 ml blood/ml oxygen) is significantly (P < 0.01) greater than that in the halothane (32+/- 8) and sevoflurane (31+/-8) groups. When compared at 1.5 MAC, the average value of Pjvo2in the isoflurane group (55+/-5 mmHg) is significantly (P < 0.01) greater than that in the sevoflurane group (48 +/-6), but it was not significantly different from that in the halothane group (50+/-4).
Figure 1. Time course of the changes of cerebral blood flow (CBF) equivalent and internal jugular venous oxygen tension (Pjvo2). Values are expressed as mean+/-SD. CBF equivalents at 0.5 MAC of isoflurane, halothane, and sevoflurane were 21+/-4, 20+/- 3, and 21+/-5 ml blood/ml oxygen, respectively. CBF equivalent and Pjvo2significantly (P < 0.01) increased in a dose-dependent manner volatile anesthetic concentrations (0.5, 1.0, 1.5 MAC). Once anesthetic concentration reached 1.5 MAC, the increase in CBF equivalent and Pjvo2in all groups were maintained increased with minimal fluctuation. When compared at 1.5 MAC, the average value of CBF equivalent in the isoflurane group (45+/-8 ml blood/ml oxygen) is significantly (P < 0.01) greater than that in the halothane (32+/- 8) and sevoflurane (31+/-8) groups. When compared at 1.5 MAC, the average value of Pjvo2in the isoflurane group (55+/-5 mmHg) is significantly (P < 0.01) greater than that in the sevoflurane group (48 +/-6), but it was not significantly different from that in the halothane group (50+/-4).
Figure 1. Time course of the changes of cerebral blood flow (CBF) equivalent and internal jugular venous oxygen tension (Pjvo2). Values are expressed as mean+/-SD. CBF equivalents at 0.5 MAC of isoflurane, halothane, and sevoflurane were 21+/-4, 20+/- 3, and 21+/-5 ml blood/ml oxygen, respectively. CBF equivalent and Pjvo2significantly (P < 0.01) increased in a dose-dependent manner volatile anesthetic concentrations (0.5, 1.0, 1.5 MAC). Once anesthetic concentration reached 1.5 MAC, the increase in CBF equivalent and Pjvo2in all groups were maintained increased with minimal fluctuation. When compared at 1.5 MAC, the average value of CBF equivalent in the isoflurane group (45+/-8 ml blood/ml oxygen) is significantly (P < 0.01) greater than that in the halothane (32+/- 8) and sevoflurane (31+/-8) groups. When compared at 1.5 MAC, the average value of Pjvo2in the isoflurane group (55+/-5 mmHg) is significantly (P < 0.01) greater than that in the sevoflurane group (48 +/-6), but it was not significantly different from that in the halothane group (50+/-4).
×
Figure 2. Representative electroencephalograms at 1 and 4 h of anesthesia at 1.5 MAC. Electroencephalogram (EEG) recordings showed frequent burst (sharp or spike wave, 50–100 micro V) and suppression in the isoflurane group, whereas in the halothane and sevoflurane groups, 13–15-Hz (50–100 micro V) and 9–13-Hz activities (70–100 micro V) were predominant, respectively. There were no apparent changes in EEG pattern with time in all three groups.
Figure 2. Representative electroencephalograms at 1 and 4 h of anesthesia at 1.5 MAC. Electroencephalogram (EEG) recordings showed frequent burst (sharp or spike wave, 50–100 micro V) and suppression in the isoflurane group, whereas in the halothane and sevoflurane groups, 13–15-Hz (50–100 micro V) and 9–13-Hz activities (70–100 micro V) were predominant, respectively. There were no apparent changes in EEG pattern with time in all three groups.
Figure 2. Representative electroencephalograms at 1 and 4 h of anesthesia at 1.5 MAC. Electroencephalogram (EEG) recordings showed frequent burst (sharp or spike wave, 50–100 micro V) and suppression in the isoflurane group, whereas in the halothane and sevoflurane groups, 13–15-Hz (50–100 micro V) and 9–13-Hz activities (70–100 micro V) were predominant, respectively. There were no apparent changes in EEG pattern with time in all three groups.
×
Table 1. Demographic and Intraoperative Data
Image not available
Table 1. Demographic and Intraoperative Data
×
Table 2. Physiologic Variables
Image not available
Table 2. Physiologic Variables
×